Rutaecarpine (MOL002662) can inhibit the production of pro-inflammatory factors IL6 and IL1B, thereby reducing the inflammatory response and oxidative stress caused by cerebral ischemia–reperfusion (CI/R) and increasing the levels of anti-inflammatory factors and superoxide dismutase (Han et al., 2019). This evidence concerns the gene IL1B and brain ischemia.